Lineage Cell Therapeutics, Inc. (LCTX) Q2 2026 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2026 Earnings Call Transcript
Lineage Cell (LCTX) Reports Q2 Loss, Lags Revenue Estimates
Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.01 per share a year ago.
Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript
Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.02 per share a year ago.
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript
Lineage Cell (LCTX) Reports Break-Even Earnings for Q4
Lineage Cell (LCTX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.01 per share a year ago.
Lineage Cell Therapeutics, Inc. (LCTX) Q3 2025 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. ( LCTX ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Ioana Hone - Director of Investor Relations Brian Culley - CEO, President & Director Jill Howe - CFO & Principal Financial and Accounting Officer Conference Call Participants William Wood - B. Riley Securities, Inc., Research Division Joseph Pantginis - H.C.
Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates
Lineage Cell (LCTX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.02 per share a year ago.
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2025 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Brian M. Culley - CEO, President & Director Ioana C.
Lineage Cell (LCTX) Reports Q2 Loss, Beats Revenue Estimates
Lineage Cell (LCTX) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.03 per share a year ago.
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
Lineage Cell (LCTX) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.04 per share a year ago.
